Wednesday, July 8, 2026

pharma · Multiple Sclerosis · Relapsing Remitting Multiple Sclerosis · CTNM

Contineum Therapeutics

Contineum Therapeutics patent portfolio — 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

San Diego, USA HQ
2017 Founded
59 Employees
Public company Type
CTNM · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2017
Employees
59
Programs
7
Drugs
3
Patents
2
Intelligence · Patents

Contineum Therapeutics patents

2 pharmaceutical patents indexed for Contineum Therapeutics. 0 expire within 24 months.

Contineum Therapeutics has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Patent portfolio

  1. US 12390462

    Muscarinic acetylcholine M1 receptor antagonists

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12054487

    Muscarinic acetylcholine M1 receptor antagonists

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Contineum Therapeutics have?

2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Contineum Therapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.